Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial

Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial

<p><b>Objective</b></p> Deucravacitinib, a tyrosine kinase 2 inhibitor, was assessed in a phase 2 trial in patients with active psoriatic arthritis (PsA). Here, we report effects of deucravacitinib from the patient perspective. <p><b>Methods</b></p> T...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, V, Gossec, L, Coates, LC, Ogdie, A, Choi, J, Becker, B, Zhuo, J, Lehman, T, Nowak, M, Elegbe, A, Mease, PJ, Deodhar, A
Formato: Journal article
Lenguaje:English
Publicado: Wiley 2024

Ejemplares similares

Ejemplares similares